Balasa Dinverno & Foltz’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Balasa Dinverno & Foltz’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$360K	Sell	5,814 -2,603	-31%	-$182K	0.02%	239
2022 Q2	$671K	Sell	8,417 -435	-5%	-$41.2K	0.04%	165
2022 Q1	$931K	Sell	8,852 -894	-9%	-$87.1K	0.06%	137
2021 Q4	$1.05M	Sell	9,746 -284	-3%	-$31K	0.07%	121
2021 Q3	$1.1M	Sell	10,030 -177	-2%	-$18.4K	0.08%	114
2021 Q2	$956K	Sell	10,207 -575	-5%	-$52.9K	0.07%	128
2021 Q1	$992K	Sell	10,782 -1,464	-12%	-$124K	0.08%	117
2020 Q4	$896K	Sell	12,246 -1,498	-11%	-$111K	0.07%	116
2020 Q3	$1.07M	Buy	+13,744	New	+$946K	0.1%	89
2018 Q4	–	Sell	-13,000	Closed	-$255K	–	252
2018 Q3	$255K	Sell	13,000 -27,000	-68%	-$513K	0.03%	208
2018 Q2	$662K	Sell	40,000 -9,000	-18%	-$137K	0.1%	99
2018 Q1	$696K	Hold	49,000	–	–	0.11%	88
2017 Q4	$715K	Sell	49,000 -1,000	-2%	-$14K	0.11%	86
2017 Q3	$634K	Hold	50,000	–	–	0.1%	91
2017 Q2	$593K	Hold	50,000	–	–	0.1%	92
2017 Q1	$739K	Hold	50,000	–	–	0.12%	74
2016 Q4	$809K	Hold	50,000	–	–	0.14%	65
2016 Q3	$906K	Sell	50,000 -22,000	-31%	-$430K	0.17%	57
2016 Q2	$1.19M	Sell	72,000 -53,464	-43%	-$865K	0.21%	38
2016 Q1	$2.08M	Sell	125,464 -25,000	-17%	-$437K	0.37%	18
2015 Q4	$3.26M	Hold	150,464	–	–	0.55%	15
2015 Q3	$2.98M	Sell	150,464 -50,100	-25%	-$1.58M	0.53%	14
2015 Q2	$6.97M	Hold	200,564	–	–	1.13%	11
2015 Q1	$5.21M	Hold	200,564	–	–	0.74%	15
2014 Q4	$2.58M	Sell	200,564 -194,931	-49%	-$2.44M	0.37%	21
2014 Q3	$4.86M	Buy	+395,495	New	+$4.6M	0.74%	14

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Balasa Dinverno & Foltz's HZNP Position: Q3 2022 in Review

Balasa Dinverno & Foltz reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 31% in Q3 2022, selling an estimated $182K and leaving 5,814 shares worth $360K. The position accounts for 0.02% of the portfolio, ranked #239.

Balasa Dinverno & Foltz first reported a position in HZNP in Q3 2014 and has held it in 26 quarters since. The position peaked at $6.97M in Q2 2015. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Balasa Dinverno & Foltz held 5,814 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $360K as of Q3 2022.
Balasa Dinverno & Foltz sold 2,603 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $182K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #239 holding.
Balasa Dinverno & Foltz first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and has held it in 26 quarters since.
Balasa Dinverno & Foltz's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.97M in Q2 2015.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.